Forty-four percent of the fibrillin-I gene (FBN1) from 19 unrelated families with Marfan syndrome was screened for putative mutations by single strand conformational polymorphism (SSCP) analysis.
Marfan syndrome is an autosomal dominant connective tissue disorder primarily involving the cardiovascular, ocular, and skeletal systems.' If untreated, it shortens life expectancy mainly because of cardiovascular complications. Published incidences range between 1 in 5000 and 1 in 10 000 live births.2 3The phenotype represents a continuum, one end of which merges with the normal population. Mutations in the gene coding for fibrillin-I on chromosome 15 (FBN1) are responsible for Marfan syndrome,'5 the rare neonatal Marfan syndrome,7 8and some cases each of autosomal dominant ectopia lentis,7 isolated familial aortic aneurysms,9 and isolated skeletal features of Marfan syndrome.'0 Fibrillin is the major structural component of [10] [11] [12] nm microfibrils of the extracellular matrix." It has a highly repetitive structure, including 47 epidermal growth factor (EGF)-like motifs, seven cysteine rich transforming growth factor-[l binding protein (TGF-,B1 BP) motifs, and two hybrid motifs. EGF-like motifs, which comprise the major building blocks of the fibrillin-l protein, display calcium binding properties.'2 '3 With two exceptions, FBN1 mutations described so far have been 665 unique to each family, occurring randomly over the entire length of the gene.2 14
We report the clinical features of five Marfan syndrome patients from four families and characterisation of their respective putative FBN1 substitution mutations in the light of current knowledge, with particular reference to genotype-phenotype correlation.
Materials and methods

THE PATIENTS
The five patients in whom a FBN1 mutation was characterised are described below. None had homocystine in their urine.
Patient 1 A diagnosis of Marfan syndrome was not suspected in this 31 year old woman until the diagnosis was made in her son (patient 2) at 10 years of age. Although asymptomatic and not considered to have Marfan syndrome on clinical grounds, an echocardiogram confirmed aortic root dilatation and aortic incompetence. Her height was 174.5 cm (97th centile), arm span 174.5 cm, upper:lower segment ratio 0.97, and mid-finger and hand lengths 9 cm and 20.5 cm, respectively (>97th centile). Slit lamp examination showed bilateral lens dislocation. She was treated with propranolol and had regular echocardiographic surveillance. A Bentall's procedure (composite aortic graft repair and aortic valve replacement) was performed at 37 years of age when the aortic root diameter (ARD) was 6 cm.
Patient 2
The diagnosis of Marfan syndrome was first suspected in this boy at the age of 10 years, because of his high, narrow palate, tall stature, dolichostenomelia, arachnodactyly, thoracic scoliosis, and combined pectus excavatum/ carinatum defect. Echocardiogram showed aortic root dilatation, mild mitral valve prolapse, and mild mitral incompetence. Slit lamp examination showed bilateral lens dislocation. Radiograph of the spine showed hypoplasia of the posterior elements of C 1. He had limitation of neck extension, progressive contracture of both elbow joints, hypermobility of the distal interphalangeal joints, and fixed flexion deformities of the proximal interphalangeal joints of both index fingers. He required orthodontic treatment, bilateral lens aspiration, and surgery to widen the palate. His clinical phenotype was more severe than that of his mother. At the age of 19 years, his height was 188 cm (90th-97th centile), upper:lower segment ratio 0.81, and mid-finger and hand lengths 9.5 cm and 21.5 cm, respectively (>97th centile). He had marked striae distensae over the hips, thighs, and lumbar region. There was progressive aortic root dilatation (ARD 4.9 cm; normal <3.7 cm) and at the age of 21 years, aortic graft surgery is being planned.
Patient 3 A diagnosis of Marfan syndrome was made at the age of 5 years, based on clinical features of tall stature, myopia, bilateral lens dislocation, a high arched palate, arachnodactyly, and bilateral inguinal herniae. The patient was abroad with his family until the age of 13 years and, on return, echocardiography showed dilatation of the aortic root (ARD 3.4, 3.6 (95th centile 3.2 cm) and 3.8 cm (95th centile 3.6 cm), at 13 Echocardiography at 3 years of age showed aortic root dilatation and mitral valve prolapse and led to a revised diagnosis of Marfan syndrome. Ophthalmological examination at 4 years confirmed myopic astigmatism and amblyopia of the right eye. The pupils could not be fully dilated because of iris dilator atrophy and, consequently, lens dislocation could not be excluded. He had a lean body build, generalised joint laxity, long narrow feet, and slender fingers. There was an asymmetrical pectus carinatum defect associated with prominence of the sternocostal junction. The accelerated growth had ceased. He was treated with verapamil, as asthma precluded treatment with f blockers.
At the age of 6.5 years (fig 1) , his HC was 57.5 cm, height 129.5 cm (both >97th centile), arm span 131 cm, upper:lower segment ratio 0.96, mid-finger length 6 cm (75th centile), and hand and foot lengths 15.4 cm and 20.5 cm, respectively (both 97th centile). At 7.5 years of age, the ARD measured 3.4 cm (95th centile 2.45 cm) and psychometric assessment (WISC-III) resulted in an overall score within the average range of intellectual abilities, with verbal expression above average for age.
Since the age of 9 to 10 months, he had episodes of cyanosis, pallor, and nausea with or without vomiting, headache, and sleepiness. Sleep studies at the age of 7 years excluded the possibility of obstructive apnoea. Cardiac re-evaluation could not identify a cause for the episodes, and a follow up CT scan at 8 years (fig 2A) was the second child of non-consanguineous parents. Her BW was 3200 g (50th centile), HC 36.8 cm (97th centile), and crown-heel length 55 cm (97th centile), taking limb contractures into consideration. There was a relative lack of subcutaneous fat. The ears were long (4.5 cm) and soft with hypoplastic cartilage. The limbs were long, there was arachnodactyly ( fig 2B) , and the hand (7.5 cm), mid-finger (3.5 cm), and foot (9.3 cm) lengths were all greater than the 97th centile. There was ulnar deviation of the fingers, flexion contractures of the shoulders, elbows, hips, knees, and ankles, and camptodactyly and flexion contractures of the toes. The skin was redundant and loose. Ophthalmological examination showed poor dilator muscle of the pupils but no lens dislocation. A chest radiograph showed eventration of the right hemidiaphragm, slender long bones, and gracile ribs. Echocardiogram showed hypokinesia of both ventricles, a flared and mildly dilated aortic root (ARD 1.4 cm), a normal aortic valve, prolapse of both mitral valve leaflets, mild mitral regurgitation, and moderate tricuspid valve prolapse with mild regurgitation. Cranial ultrasound was normal apart from an enlarged cisterna magna. She died at home (cause unknown) at the age of 2 months with no apparent preceding illness. The parents declined skin biopsy and necropsy.
GENOMIC DNA EXTRACTION AND PCR AMPLIFICATION DNA was extracted from peripheral blood leucocytes from the probands and parents after obtaining informed consent. Genomic DNA samples were amplified by PCR and the products subjected to single strand conformational polymorphism (SSCP) analysis. All PCRs were performed using selected intron based exon specific primers. Primers were designed according to published sequence data. ' Ready Reaction Dye Primer Cycle Sequencing Kit protocol (Applied Biosystems). Initially, cycle sequencing was undertaken using primers in either the forward or reverse direction. Once a sequence alteration was found, cycle sequencing using the alternate primer was performed to confirm the mutation. For exon 25, the amplified DNA fragment (patient 5) used for direct sequencing was purified using the reagents and protocol of the Qiaquick (Qiagen) PCR Purification Kit Protocol (Bresatec) in a 100 gl reaction volume. Cycle sequencing was used to produce fluorescently labelled double stranded PCR product using the reagents and conditions specified in the Taq DyeDeoxy. Terminator Cycle Sequencing Kit protocol (Applied Biosystems).
The purified and fluorescently labelled dideoxy terminated or dye primer PCR fragments were separated on a 6% sequencing gel and sequenced using an ABI automated DNA sequencer model 373A. DNA fragments with a point mutation were sequenced using both forward and reverse amplification primers to confirm the mutation. Sequence data were visualised as a four colour chromatogram, and then compared to normal FBN1 gene cDNA sequence obtained from Genbank database (Genbank database accession number L13923; complete coding sequence of HUM-FIBRILLIN Homo sapiens fibrillin mRNA). RESTRICTION arrow indicates site of enzyme cleavage) and the C71 IY mutation was predicted to abolish this site (altered sequence: 5'...CTCCAG ...3') in the mutant allele in affected patients. Exon 17 specific PCR amplification products of genomic DNA from six unaffected subjects and patients 1 and 2 were subjected to restriction digestion with PstI, and electrophoresed through a 3% agarose gel stained with ethidium bromide. In unaffected subjects with two intact PstI sites, PstI digestion yielded two digested fragments whose sizes (57 and 76 bp) together added up to the size of the undigested PCR product (133 bp). In patients 1 and 2 with the C71 1Y mutation, the PstI digest showed the three bands predicted, providing further verification of the putative mutation C711Y.
A705T MISSENSE MUTATION: SPORADIC CLASSICAL MARFAN SYNDROME (PATIENT 3) Sequence analysis of this 257 bp fragment showed a heterozygous G to A single base substitution at nucleotide 2113. This change predicts an A705T missense mutation that alters the wild type alanine (non-polar) to a threonine (uncharged polar) amino acid in the last codon of exon 16, adjacent to the GT splice site. Sequencing of plasmid DNA from the unaffected mother gave normal results. C 11 52y MISSENSE MUTATION: SEVERE MARFAN SYNDROME (PATIENT 4) Sequence analysis of this 181 bp fragment showed a heterozygous G to A single base substitution at nucleotide 3458 (corresponding to amino acid 1152). The C1152Y missense mutation predicts an alteration of the wild type cysteine amino acid to a tyrosine. Since the patient is adopted, there was no ready recourse to comparative sequence analysis of DNA from the biological parents. However, sequencing from an unaffected control gave normal results.
C1055G MISSENSE MUTATION: NEONATAL MARFAN SYNDROME (PATIENT 5) Direct DNA sequencing and analysis of exon 25 PCR amplified fragments (273 bp) in forward and reverse directions showed a heterozygous T to G single base substitution at nucleotide 3163, which is predicted to result in a C1055G substitution in one of the calcium binding (cb)EGF-like domains constituting 12 such consecutive motifs in the central portion of the FBN1 gene. The C1055G substitution alters the wild type cysteine to a glycine amino acid.
Discussion
We have characterised four novel FBN1 mutations in five Marfan syndrome patients. Two members of a family with classical Marfan syndrome have different disease severity, with the son more severely affected than his mother. A third patient has a classical Marfan phenotype, presumably caused by a de novo FBN1 mutation. These three patients have mutations within the second TGF-1 BP motif of FBN1, a region in which no FBN1 mutations have hitherto been described. The fourth patient manifested clinical features in the neonatal period but it was some years before a correct diagnosis was assigned. The last patient had neonatal Marfan syndrome and died at 2 months of age. These latter two patients, both with severe phenotypes, had a mutation affecting an EGF-like repeat in the central portion of the FBN1 gene.
CLASSICAL MARFAN SYNDROME Two novel heterozygous mutations, A705T and C71 Y, were identified in three patients with classical Marfan syndrome (patients 1, 2, and 3). The A705T and C71 1Y mutations at exons 16 and 17, respectively, are the first reported in the second TGF-p1 BP motif.
There are six other mutations reported in TGF-f31 BP motifs of FBN1. The third and fourth TGF-, 1 BP motifs flank 12 consecutive cb-EGF motifs in the central portion of the FBN1 gene. The mutations G1013R and K1023N both occur in the third TGF-1I BP motif, corresponding to exon 24. Both are associated with a severe neonatal phenotype. The C1589F mutation (exon 38) and a 4 bp insertion mutation (exon 41) that leads to a premature termination codon occur in the fourth and fifth TGF-,B1 BP motifs, respectively, and both are associated with a classical Marfan phenotype. Mutations Y2113X and del ex 51 both occur in the sixth TGF-11 BP motif, corresponding to exon 51, and are associated with classical Marfan syndrome2 (FBN1 mutations reported to Marfan syndrome and related disorders research consortium). There are no reported mutations involving the first or last (seventh) TGF-p1 BP motifs.
The A705T de novo mutation leads to substitution of a non-polar alanine for an uncharged polar threonine residue in the second TGF-, 1 BP motif of FBN1. The wild type alanine is located precisely five codons up and downstream from two conserved cysteine residues. This cysteine rich TGF-f31 BP domain may participate in protein-protein interactions, and the nature and location of the A705T mutation may be responsible for disrupted domain conformation.
Of the mutations identified in TGF-f31 BP motifs, only the C1589F and C711Y alter a wild type cysteine residue. Interestingly, both mutations occur at the same cysteine residue in their respective TGF-,B1 BP motifs, suggesting that this cysteine may have a critical function within these motifs. The C7 11Y mutation occurs at the eighth cysteine residue of the second TGF-f 1 BP motif, while the C1589F substitution occurs at the eighth cysteine of the fourth TGF-R1 BP-like domain of fibrillin. '8 The latter patient had congenital contractures but no skeletal or ocular findings, and was diagnosed with Marfan syndrome when he developed aortic root dilatation. Fibrillin protein biosynthesis studies of dermal fibroblasts showed a normal rate of synthesis, delayed secretion, and fibrillin deposition into microfibrils of about 65% of normal.'9 The familial C7 11Y mutation is responsible for a classical Marfan phenotype in mother and son. However, the son, with significant pain and limitation of movement of the upper cervical spine, and impending prophylactic aortic graft surgery for progressive aortic root dilatation, is clearly more severely affected than his mother. This illustrates the well recognised intrafamilial variability in Marfan syndrome, despite the presence of an identical FBN1 mutation.
NEONATAL AND SEVERE MARFAN SYNDROME Two novel mutations were identified, one in a patient with a severe Marfan phenotype (patient 4), and the other in a patient with neonatal Marfan syndrome (patient 5). Interestingly, both patients had iris dilator hypoplasia. Awareness of the association of this congenital finding with Marfan syndrome20may have led to an earlier diagnosis in patient 4. Patient 5 had eventration of the hemidiaphragm, a feature which has been described only rarely in Marfan syndrome.2' Despite a relatively severe phenotype, patient 4 (adopted) has survived beyond the neonatal period. Parental DNA was not available but since neither natural parent is known to have Marfan syndrome (personal communication with natural parents), the possibility that he could represent a compound heterozygote was considered unlikely. There has been one report of a rare compound heterozygote Marfan patient (lethal phenotype), born to non-consanguineous parents with classical Marfan syndrome.22 The two characterised FBN1 mutations in that infant show incomplete dominance of FBN1 mutations and this highlights the fact that the normal allele plays a significant role in ameliorating the disease process in Marfan syndrome.
The mutations in patients 4 mutations that substitute cysteine residues are less likely to cause severe disease than those which alter other residues.'4 The C1055G and C I 152Y mutations both alter a wild type cysteine, yet each is associated with a severe clinical phenotype. These findings appear contrary to published reports which suggest that, in general, cysteine substitutions cause a severe phenotype only when they occur at the aminoor carboxy-terminus of the FBN1 gene, the proposed sites of nucleation for microfibrillar assembly.2 14 However, it has also been suggested that the location rather than the character of the mutation might be the more influential factor in determining phenotypic severity.7 '4 It is probable that mutations in the region between exons 24 and 32, which cause a severe phenotype, can affect the structure of the the fibrillin monomer over a wide distance. One reported mutation in neonatal Marfan syndrome occurs in exon 25 and involves a 3 bp insertion of a cysteine into an EGF domain.8 This insertion mutation is located 11 bases (four amino acids) downstream from the substitution mutation C1055G defined in patient 5 
